Skip to main content
. 2021 Sep 17;9(9):1031. doi: 10.3390/vaccines9091031

Figure 2.

Figure 2

Mean levels of SARS-CoV-2 spike protein RBD-specific IgG antibodies post vaccination according to pre-vaccinal COVID-19 status, and post infection. (A)—in recipients of BNT-162b2, BBIBP-CorV, ChAdOx1-S, and Gam-COVID-Vac vaccines at 6 weeks post vaccination, as compared with non-vaccinated individuals with past COVID-19 at 6 weeks post infection. (B)—kinetics of antibody levels in recipients of BNT-162b2 and BBIBP-CorV from 6 weeks to 3 months post-vaccination, and in non-vaccinated individuals with past COVID-19 from 6 weeks to 3 months post infection. (C)—in recipients of BNT-162b2 and BBIBP-CorV at 3 months post vaccination, as compared with non-vaccinated individuals with past COVID-19 at 3 months post infection. (A–C)—Sample sizes are shown above standard deviation (SD) error bars. Horizontal line at an index of 1 indicates test cut-off. * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; ns—non-significant; wks—weeks; mos—months.